>With a deal like this, I would think that NVS could have bought all of DYAX and own its human-phage display technology<
They may have considered that. Perhaps NVS thinks MorphoSys’ technology is superior to phage display. Moreover, NVS may have little interest in paying a premium for DYAX’s HAE program, which DYAX would surely demand. Regards, Dew
In retrospect, the IP license between these companies announced two weeks ago pointed toward a major antibody deal by MorphoSys. So much so that it would’ve been a fine trade to buy MorphoSys for this reason alone. I infer that the NVS-MorphoSys deal was ready to go except for the final piece afforded by the IP license from DYAX.
>> The agreement grants MorphoSys a fully paid-up license to a variety of phage display-related patents from Dyax as well as other patents, including several relating to methods for displaying and selecting antibodies and other proteins through the use of alternative types of display. As part of the license agreement, MorphoSys gains the right to sublicense the patents in conjunction with its proprietary technology. The license agreement provides MorphoSys with flexibility for future technology development to further diversify its antibody technology portfolio and improve its offering for therapeutic, diagnostic and research customers. <<
So, in answer to your question about whether NVS considered buying DYAX instead of doing a deal with MorphoSys, I now think the answer is probably not. It looks like NVS wanted MorphoSys’ technology platform and wanted to assure that acquiring it would not run afoul of DYAX’s IP. Regards, Dew
News 
Market Data 
Discover 
AI
